DPP4 inhibitors and cardiovascular outcomes: safety on heart failure

Chang Xia, Aditya Goud, Jason D’Souza, Chanukya H. Dahagam, Xiaoquan Rao, Sanjay Rajagopalan, Jixin Zhong

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.

Original languageEnglish (US)
Pages (from-to)299-304
Number of pages6
JournalHeart Failure Reviews
Issue number3
StatePublished - May 1 2017


  • Cardiovascular outcomes
  • DPP4
  • Heart failure
  • Incretin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'DPP4 inhibitors and cardiovascular outcomes: safety on heart failure'. Together they form a unique fingerprint.

Cite this